This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lyman, G. H. Search for Related Content PubMed Articles by Lyman, G. H.

Undertreatment of Cancer Patients With Chemotherapy Is a Global Concern

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Gary H. Lyman, MD, MPH

The efficacy of cancer chemotherapy is generally established on the basis of randomized controlled clinical trials evaluating a particular drug or combination using a specific dose and schedule. In adult patients with cancer, drug dosing has traditionally been based on a patient's estimated body-surface area (BSA), although there are little data supporting such a strategy. Despite continuing controversy concerning the value of dose escalation and intensification schedules, there exists compelling preclinical and clinical evidence indicating that reductions in standard dose intensity may compromise disease-free and overall survival in the curative setting.^1–4 In practice, however, the . . . [Click for More]

This article has been cited by other articles:

				G. H. Lyman Caring for the Elderly Cancer Patient: Training the Next Generation of Oncologists J. Oncol. Pract, July 1, 2008; 4(4): 193 - 194. [Full Text] [PDF]

				D. W. Blayney See You in Chicago J. Oncol. Pract, May 1, 2008; 4(3): 107 - 107. [Full Text] [PDF]